Indication
Non-Small Cell Lung Cancer Lymphoma
1 clinical trial
2 products
Product
mRNA-2752Clinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint BlockadeStatus: Active (not recruiting), Estimated PCD: 2024-05-15
Product
Durvalumab